1996
DOI: 10.1046/j.1365-2141.1996.d01-1891.x
|View full text |Cite
|
Sign up to set email alerts
|

Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma

Abstract: Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) have been reported after autologous transplantation (AT) for lymphoma. It is not clear whether myeloablative therapy used in conjunction with autologous transplantation contributes to the development of MDS/AML or whether the conventional chemotherapy preceding the transplant, and administered over a prolonged period, causes these secondary malignancies. To address this issue, we examined 188 patients with multiple myeloma (MM) who had received … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
81
0
6

Year Published

1999
1999
2021
2021

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 151 publications
(90 citation statements)
references
References 0 publications
3
81
0
6
Order By: Relevance
“…Three of the patients had responding myeloma and, in retrospect, a del(5q) chromosome abnormality, a characteristic cytogenetic aberration in myeloma patients subsequent to prolonged standard-dose melphalan treatment (Govindarajan et al, 1996;Amiel et al, 1999). Despite published data indicating the efficacy of thalidomide in subsets of patients with MDS or AML (Zorat et al, 2001;Steins et al, 2002;Strupp et al, 2002), our observations suggest that thalidomide, at least in combination with dexamethasone and cyclophosphamide, does not control and may even adversely affect concurrent MDS/sAML.…”
Section: Discussionmentioning
confidence: 55%
“…Three of the patients had responding myeloma and, in retrospect, a del(5q) chromosome abnormality, a characteristic cytogenetic aberration in myeloma patients subsequent to prolonged standard-dose melphalan treatment (Govindarajan et al, 1996;Amiel et al, 1999). Despite published data indicating the efficacy of thalidomide in subsets of patients with MDS or AML (Zorat et al, 2001;Steins et al, 2002;Strupp et al, 2002), our observations suggest that thalidomide, at least in combination with dexamethasone and cyclophosphamide, does not control and may even adversely affect concurrent MDS/sAML.…”
Section: Discussionmentioning
confidence: 55%
“…Keywords: autologous transplantation; myelodysplastic features; FAB criteria; myelodysplastic syndromes Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are increasingly recognized as a late complication of stem cell transplantation. [1][2][3][4][5][6][7][8][9][10] Diagnosis of de novo MDS is usually based on the criteria of the French-American-British (FAB) Co-operative Group. 11 When patients present with peripheral cytopenias and dysplastic features alone in bone marrow and peripheral blood a diagnosis of refractory anaemia (RA) can be made (some of these cases may also have ring sideroblasts, RAS).…”
mentioning
confidence: 99%
“…It was also shown by these authors to concern only M with IgG or IgA M-protein. Among possible favoring factors, high-dose melphalan involved in the procedure of auto-SCT was first suspected [5]. In the era of immunomodulating drugs (imids) and especially lenalidomide, Reece and Goswami reported MDS/AML in 2.6% of patients treated with lenalidomide for refractory/relapsed MM, at a median of 76 months from the time of MM diagnosis [6].…”
Section: Discussionmentioning
confidence: 99%